Sodium-glucose co-transporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: A randomized, open-label, 3-arm parallel comparative, exploratory study

Diabetes, Obesity and Metabolism

Volumn 19, Issue 5, 2017, Pages 739-743

  Yabe, Daisuke ^a,b,c   Iwasaki, Masahiro ^a,b   Kuwata, Hitoshi ^a,b   Haraguchi, Takuya ^b   Hamamoto, Yoshiyuki ^a,b   Kurose, Takeshi ^a,b   Sumita, Kiminobu ^d   Yamazato, Hitoshi ^d   Kanada, Shigeto ^d   Seino, Yutaka ^a,b  

^a Kobe Biotechnology Research and Human Resource Development Center   (Japan)

^b KANSAI ELECTRIC POWER CO   (Japan)

^c KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d Medical Corporation Heishinkai OCROM Clinic   (Japan)

Author keywords

carbohydrate intake; continuous glucose monitoring; glucose variability; glycaemic index; luseogliflozin; SGLT2 inhibitor; type 2 diabetes

Indexed keywords

GLUCAGON; GLUCOSE; INSULIN; KETONE BODY; LUSEOGLIFLOZIN; 1,5-ANHYDRO-1-(5-(4-ETHOXYBENZYL)-2-METHOXY-4-METHYLPHENYL)-1-THIOGLUCITOL; AGENTS AFFECTING WATER, MOLECULE OR ION TRANSPORT; ANTIDIABETIC AGENT; CARBOHYDRATE DIET; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2; SORBITOL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD EXAMINATION; BLOOD GLUCOSE MONITORING; CARBOHYDRATE INTAKE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFICACY; DRUG SAFETY; EXPLORATORY RESEARCH; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; JAPANESE (PEOPLE); MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; URINARY FREQUENCY; ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; ANALYSIS; ANTAGONISTS AND INHIBITORS; BLOOD; CARBOHYDRATE DIET; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DIABETIC DIET; DIABETIC KETOACIDOSIS; DIET THERAPY; GLYCEMIC INDEX; HYPERGLYCEMIA; HYPOGLYCEMIA; JAPAN; LOW CARBOHYDRATE DIET; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PHYSIOLOGIC MONITORING; PROCEDURES;

BLOOD GLUCOSE; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; DIABETIC KETOACIDOSIS; DIET, CARBOHYDRATE-RESTRICTED; DIET, DIABETIC; DIETARY CARBOHYDRATES; FEMALE; GLYCEMIC INDEX; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; JAPAN; KETONE BODIES; MALE; MEMBRANE TRANSPORT MODULATORS; MIDDLE AGED; MONITORING, PHYSIOLOGIC; SODIUM-GLUCOSE TRANSPORTER 2; SORBITOL;

EID: 85013497959     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12848     Document Type: Article

References (16)

1. Fujita Y, Inagaki N. Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: clinical data and mechanism of action. J Diabetes Invest. 2014;5:265-275.
2. Hasan FM, Alsahli M, Gerich JE. SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res Clin Pract. 2014;104:297-322.
3. Yabe D, Nishikino R, Kaneko M, Iwasaki M, Seino Y. Short-term impacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events. Expert Opin Drug Saf. 2015;14:795-800.
4. Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015;38:1638-1642.
5. Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015;100:2849-2852.
6. Ogawa W, Sakaguchi K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors. J Diabetes Invest. 2016;7:135-138.
7. Hayami T, Kato Y, Kamiya H, et al. Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet. J Diabetes Invest. 2015;6:587-590.
8. American Diabetes Association. Standards of medical care in diabetes-2016. Diabetes Care. 2016;39(suppl 1):S25-S28.
9. Tajima N, Noda M, Origasa H, et al. Evidence-based practice guideline for the treatment for diabetes in Japan 2013. Diabetol Int. 2015;6:151-187.
10. Sasaki T, Seino Y, Fukatsu A, Ubukata M, Sakai S, Samukawa Y. Pharmacokinetics, pharmacodynamics, and safety of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a randomized, single-blind, placebo-controlled trial. Adv Ther. 2015;32:319-340.
11. McDonnell CM, Donath SM, Vidmar SI, Werther GA, Cameron FJ. A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol Ther. 2005;7:253-263.
12. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124:499-508.
13. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124:509-514.
14. Nishimura R, Osonoi T, Kanada S, et al. Effects of luseogliflozin, a sodium-glucose co-transporter 2 inhibitor, on 24-h glucose variability assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, crossover study. Diabetes Obes Metab. 2015;17:800-804.
15. DeFronzo RA, Hompesch M, Kasichayanula S, et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care. 2013;36:3169-3176.
16. Pearce KL, Noakes M, Keogh J, Clifton PM. Effect of carbohydrate distribution on postprandial glucose peaks with the use of continuous glucose monitoring in type 2 diabetes. Am J Clin Nutr. 2008;87:638-644.